GlassScriptPhysician profile
Rupa Chennamaneni
NPI 1245263532
$9,435.34
in general payments reported to CMS, 2019-2025
20 companies · $19.64 in 2025
The $19.64 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,557 · 2020: $572 · 2021: $1,216 · 2022: $500 · 2023: $721 · 2024: $4,850 · 2025: $19.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,545 · Honoraria: $560 · Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,545.00 |
| Honoraria | $560.00 |
| Food and Beverage | $485.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,212.71 | 2023-2024 | Trodelvy |
| R-Pharm US LLC | $1,373.80 | 2019 | |
| Deciphera Pharmaceuticals INC. | $1,200.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $716.01 | 2021-2024 | Imfinzi |
| Lilly USA, LLC | $606.37 | 2019-2023 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $560.00 | 2023 | |
| Tempus Ai, INC | $138.40 | 2024 | |
| Seagen INC. | $132.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $92.47 | 2022 | |
| Merck Sharp & Dohme LLC | $51.17 | 2020-2022 | |
| Celgene Corporation | $40.54 | 2021-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $36.82 | 2020-2021 | |
| Pfizer INC. | $35.57 | 2019-2020 | |
| Immunomedics, INC. | $31.43 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $28.77 | 2019-2020 | |
| Genzyme Corporation | $24.40 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $20.34 | 2020 | |
| Janssen Biotech, INC. | $20.11 | 2020 | |
| Eisai INC. | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupa Chennamaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.